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In Brief
Cells are equipped with intracellular
sensing apparatuses, such as IFI16 and
RIG-I. Vitenshtein et al. show that in
response to innate cellular sensing of
HCMV and influenza viruses by these
sensors, CEACAM1 expression is
induced by the infected cells to suppress
virus production through autoregulation
of protein biosynthesis in an SHP2-
dependent manner.
Cell Reports
ReportCEACAM1-Mediated Inhibition of Virus Production
Alon Vitenshtein,1 Yiska Weisblum,2 Sebastian Hauka,3 Anne Halenius,4 Esther Oiknine-Djian,2 Pinchas Tsukerman,1
Yoav Bauman,1 Yotam Bar-On,1 Noam Stern-Ginossar,1 Jonatan Enk,1 Rona Ortenberg,5,6 Julie Tai,1 Gal Markel,5,6
Richard S. Blumberg,7 Hartmut Hengel,4 Stipan Jonjic,8 Dana G. Wolf,2 Heiko Adler,9 Robert Kammerer,10
and Ofer Mandelboim1,*
1The Lautenberg Center for General and Tumor Immunology, The BioMedical Research Institute Israel Canada of the Faculty of Medicine
(IMRIC), The Hebrew University Hadassah Medical School, 91120 Jerusalem, Israel
2Department of Clinical Microbiology and Infectious Diseases, Hadassah University Hospital, 91120 Jerusalem, Israel
3Institute for Virology, Heinrich-Heine-University, 40225 D€usseldorf, Germany
4Institute of Virology, Medical Center, University of Freiburg, 79104 Freiburg, Germany
5Ella Institute of Melanoma, Cancer Research Center Sheba Medical Center, 5262000 Tel Hashomer, Israel
6Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, 6997801 Tel Aviv, Israel
7Gastroenterology Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA
8Department of Histology and Embryology and Center for Proteomics, Faculty of Medicine, University of Rijeka, HR-51000 Rijeka, Croatia
9Helmholtz Zentrum M€unchen, German Research Center for Environmental Health (GmbH), Research Unit Gene Vectors, 81377 Munich,
Germany
10Institute of Immunology, Friedrich Loeffler Institute, Federal Research Institute for Animal Health, 17493 Greifswald-Insel Riems, Germany
*Correspondence: oferm@ekmd.huji.ac.il
http://dx.doi.org/10.1016/j.celrep.2016.05.036SUMMARY
Cells in our body can induce hundreds of antiviral
genes following virus sensing, many of which remain
largely uncharacterized. CEACAM1 has been previ-
ously shown to be induced by various innate sys-
tems; however, the reason for such tight integration
to innate sensing systems was not apparent. Here,
we show that CEACAM1 is induced following
detection of HCMV and influenza viruses by their
respective DNA and RNA innate sensors, IFI16 and
RIG-I. This induction is mediated by IRF3, which
bound to an ISRE element present in the human,
but not mouse, CEACAM1 promoter. Furthermore,
we demonstrate that, upon induction, CEACAM1
suppresses both HCMV and influenza viruses in
an SHP2-dependent process and achieves this
broad antiviral efficacy by suppressing mTOR-medi-
ated protein biosynthesis. Finally, we show that
CEACAM1 also inhibits viral spread in ex vivo human
decidua organ culture.INTRODUCTION
Non-immune cells play a critical role in the host response to
viral infection and are equipped with intrinsic sensing and
antiviral mechanisms that confer a broad resistance to a
variety of viruses (Desmet and Ishii, 2012; Honda et al., 2006;
Stetson and Medzhitov, 2006). A prominent sensor that
detects viral DNA is IFI16, which has been shown to detect
infection by human cytomegalovirus (HCMV) (Li et al., 2013).
Cells are also equipped with RNA sensing systems, such as
RIG-I, that detect a host of viruses, among them the influenzaCel
This is an open access article under the CC BY-Nvirus (Kato et al., 2006). Many of these systems converge on
IRF3 (Desmet and Ishii, 2012), which is recognized as the
master regulator of the first line of antiviral defense (Hiscott,
2007). IRF3 is constitutively expressed in almost all cells and
is poised to rapidly undergo phosphorylation, dimerization,
and translocation to the nucleus. Once in the nucleus, IRF3 ini-
tiates a limited set of primary antiviral genes such as IFN-b,
which upon secretion orchestrates the larger secondary wave
of cellular antiviral genes (Honda et al., 2006). Surprisingly,
while the ability of cells to activate effective antiviral mecha-
nisms has been known for over half a century (Isaacs and Lin-
denmann, 1957), most of the antiviral genes remain largely
uncharacterized.
Carcinoembryonic antigen-related cell adhesion molecule 1
(CEACAM1) forms homophilic interactions which deliver inhibi-
tory signals through the SHP1 (mainly in hematopoietic cells)
and SHP2 phosphatase through CEACAM1s’ immunoreceptor
tyrosine based inhibitory motifs (ITIMs) (Gray-Owen and Blum-
berg, 2006; Huber et al., 1999; M€uller et al., 2009; Nouvion
et al., 2010). Studies have shown that CEACAM1 expression
is induced very rapidly on endothelial and epithelial cells by
the NF-kB pathway following TLR4-dependent sensing of
N. gonorrhoeae infection (Muenzner et al., 2001). CEACAM1
has also been shown to be induced by IFN-g, which is selectively
secreted by T and NK cells, resulting in direct binding of IRF1
to an interferon-stimulated response element (ISRE) in the
CEACAM1 promoter (Chen et al., 1996).
Whereas theN. gonorrhoeae-mediated induction of CEACAM1
has been shown to benefit the pathogen by facilitating its binding
and infection, it remains unclear why CEACAM1 has been wired
directly to pathogen sensing systems in non-immune cells. In
the current study, we demonstrate that CEACAM1 is rapidly
inducedby innate sensingof extremely divergent viral pathogens,
the HCMV and influenza viruses, and functions as a broad sup-
pressor of viral infection.l Reports 15, 2331–2339, June 14, 2016 ª 2016 The Authors. 2331
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. HCMV DNA Induces IFI16-Mediated CEACAM1 Expression during HCMV Infection
(A) FACS staining for CEACAM1 expression at 8 and 24 HPI, on mock (Mock) or HFF cells infected with HCMV (HCMV) strains TB40/E (left) and AD169 (right)
at moi 3.
(B) Real-time PCR quantification of newly synthesized CEACAM1 transcripts in infected and 4-Thiouridine pulsed HFF cells at the designated HPI.
(C) Analysis of CEACAM1 expression on HFF cells transfected with 1 mg/ml of purified TB40/E DNA (DNA) or on HFF cells transfected with 1 mg/ml purified
UV-inactivated TB40/E DNA (UV-DNA). The Mock is HFF cells treated with transfection reagent only.
(D) Intracellular FACS analysis of IFI16 expression in TB40/E infectedHFF cells (moi 3) stably transducedwith two shRNAs targeting IFI16 (aIFI16.1/2, empty black
and red histograms) or control (Control, empty gray histogram) sequence.
(E) Quantification by FACS of the fold induction of CEACAM1 expression following infection with the TB40/E virus on cells from (D) at 3 DPI. The dotted line
represents basal mean fluorescence intensity (MFI) level on mock treated control cells that was set as 1 and to which the fold increase in expression was
compared to.
(F) Analysis of CEACAM1 expression in mock (Mock) or TB40/E (TB40, moi 3) infected ARPE-19 cells that were stably transduced with control empty vector
(empty gray histogram) and two IFI16 isoforms B (IFI16IsoB, empty black histogram) and C (IFI16IsoC, empty red histogram). The background staining was
conducted with isotype matched control antibody (background, filled gray histogram).
(A and C) The empty black and red histograms depict staining for CEACAM1 following indicated treatments (HCMV, A, DNA, or UV-DNA, C) and empty gray
histogram depicts CEACAM1 staining on mock treated cells (Mock).
(A, C, D, and F) The filled gray histogram indicates background staining with control isotype matched antibody (Bckgnd). The figures show one representative
experiment out of seven (A) or three (C, D, and F) performed.
(B and E) An average ±SD of triplicates are presented (*p < 0.05 and **p < 0.01).RESULTS
IFI16-Mediated Sensing of HCMV Infection Induces
Expression of CEACAM1
We observed that CEACAM1 expression is induced on the sur-
face of HFF cells 24 hr post infection (HPI) with HCMV laboratory
strains AD169 and TB40/E (Figure 1A) or with a clinical isolate
(Figure S1A). Analysis of transcription kinetics of newly synthe-
sized CEACAM1 mRNA showed an extremely rapid response
that was visible at 1–2 hr following infection (Figure 1B). Since a
replication-defective UV-inactivated virus, which can infect cells,
but not induce de novo viral gene transcripts, inducedCEACAM1
(Figure S1B, left histogram), we concluded that a component in
the virion was involved in CEACAM1 upregulation, but ruled out
the involvement of secreted factors since supernatant transfer
did not induce CEACAM1 (Figure S1B, right histograms). Addi-
tionally, CEACAM1 mRNA was induced even upon protein2332 Cell Reports 15, 2331–2339, June 14, 2016translation inhibition (Figure S1C), demonstrating that cellular
machinery mediating the induction was pre-formed. Importantly,
transfecting viral DNA, UV-treated or not, robustly induced the
expression of CEACAM1 (Figure 1C). This prompted us to check
whether IFI16, the innate sensor of HCMV DNA, was involved in
the induction of CEACAM1 by knocking this sensor down. Infect-
ing HFFs expressing IFI16 specific small hairpin (sh)RNAs, with
HCMV, resulted in decreased CEACAM1 induction (Figure 1E).
This indicated that IFI16 played a role in the induction of
CEACAM1. The decreased induction was specific to lack of
IFI16, as the cells were still fully responsive to other stimuli such
as polyI:C (an RNA analog that triggers the RNA sensors; Desmet
and Ishii, 2012), which induced CEACAM1 in these cells (Fig-
ure S1D). The involvement of the RNA sensing RIG-I pathway is
studied below. The ARPE-19 cell line, which is also permissive
to HCMV infection, has low levels of IFI16, and indeed,
CEACAM1 was not induced upon infection (Figure 1F). Thus,
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Figure 2. CEACAM1 Induction Is Directly Mediated by IRF3 and Occurs Also by RIG-I Sensing of Influenza Virus Infection
(A) Assessment by western blot of IRF3 levels in TB40/E infected ARPE-19IFI16IsoB cells that underwent IRF3 targeted shRNA knockdown by two clones
(aIRF3.1/2) or were transduced with control shRNA (Control, set as 100%). The upper image depicts the quantification of IRF3 levels in the lower image,
normalized to GAPDH.
(B) The TB40/E infected (3 DPI) ARPE-19IFI16IsoB cells from (A) were analyzed by FACS for induction of CEACAM1.
(C) Relative luciferase activity in ARPE-19IFI16IsoB cells, following infection with TB40/E (moi 3). The cells were transfected with either naive firefly luciferase
encoding vector (No Promoter), luciferase fused downstream to a 600 bp genomic sequence encoding the WT CEACAM1 promoter (WT pCEACAM1), or
luciferase fused to the CEACAM1 promoter mutated in the predicted IRF3 binding site (IRF3Mut pCEACAM1). The results were normalized to co-transfected
renilla luciferase and were compared to ‘‘No promoter’’ which was set as 1.
(D) Real-time PCR quantification of CEACAM1 promoter DNA sequences in anti-IRF3 ChIP of mock (Mock) and TB40/E (TB40) infected HFF cells at 4 HPI.
(E) FACS staining of A549 cells for CEACAM1 expression following infection with PR8 virus strain at moi 3 (empty black histogram) compared to mock treated
cells (empty gray histogram) or isotype matched control antibody (Bckgnd, filled gray histogram).
(F) Western blot analysis for RIG-I (aRIG-I) and IRF3 (aIRF3) expression in PR8-infected A549 cells expressing two shRNAs targeting RIG-I (aRIG-I.1/2), IRF3
(aIRF3.1/2), or control sequence (Control). The upper image is expression quantification relative to GAPDH levels.
(G and H) A549 cells infected by PR8 (3 DPI) expressing two clones of shRNAs anti-RIG-I (aRIG-I.1/2) (G) and anti-IRF3 (aIRF3.1/2) (same cells from F) (H) were
examined by FACS for the induction of CEACAM1expression.
(I) Abundance of CEACAM1 promoter sequences in anti-IRF3 ChIP of A549 cells following infection with PR8 (PR8) or mock treatment (Mock) at 3 HPI and as
quantified by real-time PCR.
(B, G, and H) The induction of CEACAM1 was calculated as the fold increase in MFI of CEACAM1 staining in shRNA-expressing cells compared to the mock
treated control shRNA transduced cells, which was set as 1 (dotted line).
(D and I) Presented values are the sequence abundance relative to the abundance in the sample prior to the ChIP (percent of input) and normalized to a quantified
control region upstream to the CEACAM1 promoter. The data presented are a representative of three (A–D, F, and I), six (E), an average ±SD of three (G and H)
independent experiments performed, and an average ±SD of three triplicates (B–D, F, and I) (**p < 0.01 and ***p < 0.001).we overexpressed in these cells the two dominant isoforms of
IFI16 (that differ in the length of the hinge region between the
DNA sensing domains; Unterholzner et al., 2010; and may affect
viral sensing efficiency). Importantly, overexpression of the IFI16
isoforms (TB40-IFI16IsoB/IsoC) was sufficient to induce CEACAM1
(Figure1F) duringHCMV infection, directly indicating that sensing
of HCMV DNA by IFI16 mediates this process.IRF3 Mediates CEACAM1 Expression
Using the IFI16-transfectant ARPE-19 cells, we next saw that
knock down of IRF3, downstream mediator of IFI16, (Figure 2A)
disrupted the upregulation of CEACAM1 during infection
(Figure 2B). This effect was specific to IRF3, and other path-
ways such as IFN-g, which induces expression of class I MHC
in an IRF3-independent manner, remained fully operationalCell Reports 15, 2331–2339, June 14, 2016 2333
(Figure S2A). Previous studies have characterized an interferon
stimulated response element (ISRE) in the CEACAM1 promoter
that binds IRF1 in response to stimulation with IFN-g (Chen
et al., 1996). Using the MatInspector algorithm (Cartharius
et al., 2005), we identified this ISRE to potentially be compatible
with the IRF3 binding sequence (Figure S2B). To investigate this
ISRE, we conducted reporter assays in which 600 bp of the wild-
type CEACAM1 promoter sequence and a promoter sequence
mutated in the ISRE site predicted to be bound by IRF3 (IRF3Mut;
Figure S2B) were fused to luciferase. While the wild-type pro-
moter sequence mediated a strong induction of luciferase activ-
ity following HCMV infection (Figure 2C), the mutation entirely
abrogated all promoter activity (Figure 2C). To check whether
IRF3 bound the CEACAM1 promoter directly, we performed
chromatin immunoprecipitation (ChIP) of IRF3. We observed
that pull down of IRF3 co-precipitated enriched CEACAM1 pro-
moter sequences in HCMV infected compared to mock cells, as
quantified by real-time PCR (Figure 2D), demonstrating that IRF3
bound the promoter directly.
Notably, the sequence and position of the ISRE in the
CEACAM1 promoter was conserved in higher primate species,
although no such site was identified in the murine promoter (Fig-
ure S2C). In line with this, no significant mCEACAM1 induction
was observed 48 HPI in various MCMV-permissive cell lines in-
fected with murine CMV (strain C3X) (Figure S2D). The antibody
used was fully functional and readily detected expression of
mouse CEACAM1 in the PD1.6 cell line (Figure S2E).
CEACAM1 Is Induced during Influenza Virus Infection
IRF3 is a component in numerous innate sensing cascades (Fig-
ure S3A). Additionally, CEACAM1 expression was seen to be up-
regulated following sensing of polyI:C (Figure S1D). Therefore,
we next checked whether CEACAM1 is induced in response to
RNA viruses such as influenza. The influenza virus can efficiently
infect only a limited number of cell lines in vitro, one of which is
lung epithelial A549 (but not HFF or ARPE-19 cells; Li et al.,
2009; that we used to study HCMV). Notably, infecting A549 cells
with the influenza A PR8 virus strain led to a robust CEACAM1
cell surface expression (Figure 2E). Knock down of the RIG-I
sensor, the RNA sensor that was shown to detect the influenza
A virus (Kato et al., 2006) (Figure 2F), showed that the induction
was dependent on this sensor (Figure 2G). This decreased
activity was specific to knock down of RIG-I since transfecting
UV-inactivated TB40/E DNA to these cells still showed a fully
operational DNA sensing response that led to a robust induction
of CEACAM1 (Figure S3B). Similar to IFI16, RIG-I also operates
through IRF3 (Figure S3A; see Desmet and Ishii, 2012) and dur-
ing CEACAM1 induction, since knock down of IRF3 (Figure 2F)
significantly inhibited its expression during the influenza virus
infection (Figure 2H). Once more, the decreased response was
specific to knock down of IRF3, as all cells were fully responsive
to IFN-g, which induces an alternative IRF3-independent
pathway (Figure S3C). Furthermore, IRF3 ChIP analysis demon-
strated direct binding of IRF3 to the CEACAM1 promoter in PR8
infected A549 cells that had enriched promoter sequences (Fig-
ure 2I). Thus, because CEACAM1 expression is paired to IRF3, it
is robustly induced by diverse innate sensing systems in
response to different viruses.2334 Cell Reports 15, 2331–2339, June 14, 2016CEACAM1 Suppresses HCMV and Influenza Virus
Production
Next, we pursued to explore why CEACAM1 is upregulated by
innate immune systems. To examine whether CEACAM1 affects
viral infection, we silenced CEACAM1 expression in HFF cells
(Figure 3A) and then infected these cells with HCMV. Importantly,
we observed that CEACAM1 suppresses HCMV, as silencing its
knockdown led to a significant elevation in virus production
(Figure 3B).
HCMV is a master of immune evasion and has recently been
shown to use its pp65 protein to evade the IFI16 innate cellular
antiviral responses (Li et al., 2013). We speculated that HCMV
might also be using the pp65 protein to evade the full antiviral ca-
pacity of CEACAM1. In linewith this, while infecting HFF cells at a
low moi with wild-type (WT) HCMV virus that did not induce
expression of CEACAM1 (compared to higher moi in previous
experiments), infection with HCMV virus deleted in the pp65 pro-
tein (Dpp65) led to a robust induction (Figure 3C). Given that
CEACAM1 is induced more efficiently on cells infected by the
Dpp65 as compared to WT HCMV, infecting CEACAM1 knock-
down cells with the Dpp65 virus could demonstrate the full anti-
viral capacity of CEACAM1. To test this, we compared the fold
change increase in viral titer in HFF cells that underwent
CEACAM1 knockdown following infection with either a WT or
Dpp65 virus. In the absence of pp65, the Dpp65 virus had a
10-fold higher fold increase in viral titer following CEACAM1
knockdown than that of the WT virus (Figure 3D). Strikingly,
CEACAM1 also suppressed the influenza virus, as knock down
of its expression in A549 cells (Figure 3E) led to a consistent
increase in influenza viral titer when infecting these cells
(Figure 3F).
Next, we investigated the mechanism of CEACAM1-mediated
inhibition of virus production. Previous studies have established
that the SHP2 phosphatase delivers the CEACAM1-inhibitory
signals in non-immune cells (Huber et al., 1999; M€uller et al.,
2009; Nouvion et al., 2010). We observed CEACAM1 to operate
through SHP2 during infectionwith HCMV and influenza, as it co-
immunoprecipitated with CEACAM1 in HFF and A549 cells
infected by these viruses (Figures S3D and S3E). Indeed,
CEACAM1 suppression of viral titer was dependent on SHP2,
as knocking down of SHP2 (Figures 3G and 3I) recapitulated
the knock down of CEACAM1 and resulted in increased viral pro-
duction during HCMV infection (Figure 3H) and influenza virus
infection (Figure 3J). Notably, knocking down SHP2 in ARPE-
19 cells, which do not induce expression of CEACAM1 upon
infection (Figure 1F), did not have any affect on HCMV viral titer
(Figures S3F and S3G). This indicated that SHP2 antiviral func-
tion was CEACAM1 dependent.
CEACAM1 Suppresses Viral Production by Regulating
Mammalian Target of Rapamycin-Mediated Cellular
Protein Translation
To understand howCEACAM1 inhibits virus production, we used
a fluorescent phospho-specific antibody array to quantify the
phosphorylation status of key components in signaling pathways
in HFF and A549 cells, in which CEACAM1 expression was
knocked down using two shRNAs and then infected with
HCMV and influenza, respectively (Figure 4A). We observed
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Figure 3. CEACAM1 Expression Suppresses Viral Replication through SHP2
(A and G) HFF cells were stably transduced with two shRNAs against CEACAM1 (A, aCEACAM1.1/2), SHP2 (G, aSHP2.1 and aSHP2.1/2), or with a control
(Control) shRNA. Knockdown was confirmed by extra- and intracellular FACS staining for CEACAM1 and SHP2, respectively, following infection with TB40/E
at moi 3.
(B and H) Plaque assay-based quantification of viral load in the supernatants of infected cells expressing CEACAM1 (B) or SHP2 (H) specific shRNAs (same cells
from A and G, respectively).
(C) Cell surface expression of CEACAM1 on HFF cells following infection (moi 0.5) with either a WT (AD169, empty gray histogram) or pp65-deleted virus (Dpp65,
empty black histogram). No staining was observed staining AD169 infected cells with isotype matched IgG (Bckgnd, filled gray histogram).
(D) Fold increase in viral titer in HFF cells (same cells from A) expressing two shRNAs against CEACAM1 (aCEACAM1.1/2) compared to viral titer in supernatant of
cells expressing control shRNA. The cells were infected with either a WT (WT) or pp65-deleted (Dpp65) AD169 virus. The fold increase in cells expressing the
aCEACAM1.1 shRNA clone infected with a WT virus was set as 1.
(E and I) A549 cells were subjected to control (Control), CEACAM1 (E, aCEACAM1.1/2), or SHP2 (I, aSHP2.1/2) specific shRNA-mediated knock down of two
clones as confirmed by FACS staining, following PR8 infection at moi 3.
(F and J) Following infection with the PR8 virus (moi 3) of cells from (E) and (I) expressing CEACAM1 or SHP2 specific shRNAs, respectively, the influenza viral titer
in supernatant was determined by an ELISA based assay. The amount of the virus present in the control transduced cells (B, F, H, and J) was set as 1. The
experiments shown are a representative of three (A–D, G, and H) and five (E, F, I, and J) independent experiments with similar results and an average ±SD of four
(B, D, and H) or eight (F and J) replicates (*p < 0.05, **p < 0.01, and ***p < 0.001).the upregulation of an activating Serine2448 phosphorylation of
mammalian target of rapamycin (mTOR) that was common dur-
ing infections with both viruses (Figure 4A). mTOR is a key regu-
lator of global cellular protein translation levels, and increased
activity of this modulator could lead to higher rates of protein
biosynthesis, which may facilitate the observed increase in viral
production (Figure 3). Investigating this option, we observed that
HFF and A549 cells stably expressing CEACAM1 and SHP2-tar-geting shRNAs, and infected with HCMV (Figure 4B) or influenza
virus (Figure 4C), exhibited a higher protein production capacity.
The observed increase in protein production was dependent on
mTOR activity, as blockingmTORwith its specific inhibitor, rapa-
mycin, prevented this increase in cells that underwent either
CEACAM1 or SHP2-knockdown during both HCMV (Figure 4B)
and influenza virus (Figure 4C) infections. We also observed
that in reciprocal experiments, overexpression of CEACAM1Cell Reports 15, 2331–2339, June 14, 2016 2335
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Figure 4. CEACAM1 Suppresses Cellular Protein Translation through Downregulation of mTOR-Activating Phospho-Serine2448 and Sup-
presses HCMV Dissemination in Human Ex Vivo Organ Culture
(A) Stably knocked down CEACAM1 (black and blue columns, aCEACAM1.1/2) or stably expressed control shRNA (gray columns, Control shRNA) in HFF
(HFFTB40) and A549 cells (A549PR8) was studied for its effects on the phosphorylation of key cellular kinases following 3 days of infection with TB40/E or PR8,
respectively, at moi 3. The cell lysates were prepared and then probed on an antibody array with specific antibodies for the phosphorylated isoforms of the
kinases listed. Using a far-red array scanner, levels of phospho-proteins were then quantified based on measurement of fluorescence emission.
(B and C) HFF cells infected with TB40/E (moi 3, B) and A549 cells infected with PR8 (moi 3, C) stably expressing control (Control), CEACAM1 (aCEACAM1.1/2), or
SHP2 (aSHP2.1/2) specific shRNAswere analyzed for total cell protein production capacity by assessing the rate of [35S]Methionine incorporation. The cells were
also administered with rapamycin at the indicated doses (Rapamycin) or with DMSO only as control treatment (Vehicle). The CPM values of cells expressing the
control shRNA were set as 100%.
(D) Confocal microscopic analysis of ex vivo organ cultured decidua at 2 DPI, which underwent infection with TB40/EGFP. The tissue sections were stained for cell
nucleus with DAPI, CEACAM1 (aCEACAM1), and cells infected with a virus were visualized by the presence of GFP (TB40-GFP). The arrowhead depicts the
HCMV infected GFPPositive cell co-expressing CEACAM1.
(E) Isolated cells from TB40/EGFP infected (TB40/EGFP, black empty histogram) and mock treated (Mock, gray empty histogram) decidua organ culture were
stained for CEACAM1 expression. The TB40/E infected cells stained with an isotype-matched control antibody served as background (Bckgnd, gray filled
histogram) staining.
(F) Cells isolated from TB40/E-infected decidua were stained with either isotype-matched control IgGs (left) or dually stained for CEACAM1 and HLA-G
expression (right).
(G and H) FACS dotplot of isolated cells from TB40/EGFP (TB40-GFP)-infected decidua organ cultures treated either with CEACAM1-Ig (CEACAM1-Ig) or control
Ig fusion protein (Control) as determined by FACS at 4 DPI and 8 DPI by (G). The number of GFPPositive cells in the gated area in the histogramwas quantified in (H).
The data are an average of three (A and C) or representative of five (B, D, and E) or three (F–H) independent experiments, and an average ±SD of three (A and H) or
six (B and C) replicates (not significant: N.S., *p < 0.05, **p < 0.01, and ***p < 0.001).(Figure S4A) and SHP2 (Figure S4C) in HFF cells led to a comple-
mentary effect of suppressed global protein production during
HCMV infection (Figures S4B and S4D). Similarly, overexpres-
sion of CEACAM1 (Figure S4E) and SHP2 (Figure S4G) in influ-
enza virus-infected A549 cells was also seen to significantly
suppress cellular protein production capacity (Figures S4F and
S4H). As viruses critically depend on the cellular protein produc-
tion machinery for their replication, we thus concluded that2336 Cell Reports 15, 2331–2339, June 14, 2016CEACAM1 suppresses HCMV and influenza virus infections by
regulating mTOR activation and subsequent levels of cellular
protein translation.
CEACAM1 Suppresses HCMV Infection in Human
Ex Vivo Organ Culture
Our final goal was to assess the physiological role of CEACAM1
in vivo. However, since mouse CEACAM1 is not induced
following infection (as it does not contain the IRF3 binding site;
Figures S2C and S2D), we proceeded with a human ex vivo
decidua (a tissue that is naturally targeted by HCMV infections
in its human host) organ culture model for HCMV infection (Fig-
ure S4I). We observed that following infection with a GFP encod-
ing TB40/E virus (TB40/EGFP), some GFPPositive infected cells
also co-expressed CEACAM1, while others did not (Figure 4D).
Staining mock and HCMV infected single cell homogenized
decidual tissues showed that following infection, CEACAM1
was also being induced in the ex vivo organ culture (Figure 4E).
To analyze which cells in the decidua upregulate CEACAM1
following infection, we stained the decidua organ cultures for
HLA-G, a marker for trophoblasts (Kovats et al., 1990). We
observed that 26.3% of HCMV-infected decidual cells were
CEACAM1Positive (9.33% CEACAM1PositiveHLA-GNegative added
to 16.97% CEACAM1PositiveHLA-GPositive cells), of which the
majority (64.5%) were HLA-GPositive 64.5% (16.97% of HLA-
GPositiveCEACAM1Positive out of 26.3% CEACAM1Positive cells)
(Figure 4F).
Finally, to test what degree of involvement CEACAM1 may
have in control of viral spread in the decidua culture, we used a
CEACAM1-Ig fusion protein, composed of the extracellular
domain of CEACAM1 fused to human IgG1 and can block
CEACAM1 function (Markel et al., 2004). To confirm the blocking
function of CEACAM1-Ig, we used the BWCEACAM1 mouse
thymoma reporter cell line, in which a construct of an extracellular
human CEACAM1 domain fused to an intracellular mouse zeta
chain was stably expressed (Figure S4J). These cells secrete
IL-2 upon crosslinking of cell surface CEACAM1, as occurred
when they were co-cultured with a CEACAM1 expressing trans-
fectant (721.221CEACAM1), but not parental (721.221Parental) cell
line (FigureS4K), given thatCEACAM1bindshomotypically.How-
ever, applying CEACAM1-Ig, and not a control fusion protein,
blocked the binding of CEACAM1 and led to a marked decrease
in the activation and IL-2 secretion by these cells (Figure S4K).
Next, we used the CEACAM1-Ig in the HCMV-infected
decidua organ cultures and determined the degree of HCMV
infection by the number of GFPPositive cells. This treatment did
not cause any observable changes in tissue structure or distribu-
tion of CEACAM1 expression (data not shown). Importantly,
however, we observed that blocking CEACAM1 interactions by
using CEACAM1-Ig led to an increased viral dissemination as
seen by an increase in the number of GFP expressing cells at 4
and 8 days (maximal days to sustain viable culture) post infection
(Figure 4G; summarized in Figure 4H). These results show ex vivo
evidence that CEACAM1 plays an important systemic role in
suppression of HCMV dissemination in infected human tissues.
DISCUSSION
In the current study, we demonstrate that CEACAM1 is strongly
integrated to innate cellular pathogen sensing systems by direct
binding of IRF3 to the CEACAM1 promoter following sensing of
HCMV by IFI16 and influenza virus by RIG-I. Given that IRF3 is a
master regulator that is activated by a wide range of innate sys-
tems, we propose that CEACAM1 is induced in response to a
very diverse spectrum of viruses. Following its expression,
CEACAM1 functions as an antiviral suppressor of both HCMVand the influenza virus. Due to the lack of an in vivo model, we
also demonstrate that CEACAM1 is induced and plays a signifi-
cant role in controlling viral spread using a human ex vivo
decidual organ culture model for HCMV infection that we have
developed (Weisblum et al., 2011). Viruses, on the other hand,
have highly honed mechanisms to evade antiviral responses,
and we show that HCMV employs the recently demonstrated
pp65 immunoevasin (Li et al., 2013) to evade the full capacity
of CEACAM1 expression and antiviral suppression. Similarly,
the influenza virus subverts cellular antiviral systems with a key
viral protein, NS1 (Mibayashi et al., 2007), that we suspect is
used to subvert full CEACAM1 functionality.
We further demonstrate that CEACAM1 and SHP2 sup-
pressed mTOR activity, a central rheostat that dictates global
levels of cellular translation (Buchkovich et al., 2008). Conse-
quently, this led to suppression of protein production in HFF
and A549 cells that were infected with HCMV and the influenza
virus, respectively. Since all viruses are fundamentally depen-
dent on cellular protein biosynthesis machinery for replication,
blocking such cellular machinery by CEACAM1 is a strategy
that could potentially be effective against a very broad range of
viruses. Although viruses strongly manipulate the translation
machinery to maintain a functionality (Clippinger et al., 2011;
Moorman et al., 2008; Walsh and Mohr, 2011), both HCMV and
influenza viruses are known to depend on mTOR activity during
specific phases of their life cycle (Burgui et al., 2007; Clippinger
et al., 2011). This renders them susceptible to translation regu-
lating mechanisms such as mediated by CEACAM1/SHP2.
Although relieving the CEACAM1/SHP2 autoregulation mecha-
nisms led to an increase in translation and viral production, it is
hard to say whether this can be attributed to the bolstering of
the mTOR-dependent stages in their lifecycle or additive
mTOR activity to pre-existing translation capacity maintained
by the viruses. It is also noteworthy that previous studies have
found, in complementation to the current study, that SHP2 func-
tions as a regulator of mTOR (Marin et al., 2008; Schramm et al.,
2012; Zito et al., 2007). However, given that SHP2 is a tyrosine
phosphatase and mTOR is activated via serine residue, this indi-
cates that SHP2 is an upstream indirect pathway activator.
The co-evolution of viruses and their hosts has led to the
development of highly diverse and sophisticated cellular defen-
sive mechanisms and viral counter-measures, examples of both
are presented here. Due to homophilic binding and self-activa-
tion, we describe here the development of a cellular mechanism
that enables an immediate and broadly effective antiviral
response by upregulation of a single protein, CEACAM1.EXPERIMENTAL PROCEDURES
Viruses, Infections, Titrations, Fluorescence-Activated Cell Sorting,
Antibody Array, Transfections, and BW Assay
HCMV, MCMV, and influenza viruses were grown, titrated, and used to infect
cells by standard procedures. Titrations were based on plaque assays for
TB40/E or ELISA based method for PR8. Stable transduction of CEACAM1,
IFI16, SHP2 transfectants, and shRNA clones (Sigma-Aldrich) was based on
lentiviral and retroviral expression systems. Fluorescence-activated cell
sorting (FACS) staining was standard protocols. For intracellular staining, a
methanol fixation based method was used. PathScan antibody array was per-
formed according to manufacturer’s instructions (Cell Signaling). Viral DNACell Reports 15, 2331–2339, June 14, 2016 2337
was transfected at 1 mg/ml. For BW assay, a 3 day 1:3 E:T ration was used with
Ig-fusion concentration of 5 mg/ml followed by IL-2 measurement (BioLegend).
See also the Supplemental Information.
Real-Time PCR, shRNAs, and Luciferase Assay
Newly synthesized transcript analysis was previously described (Halenius
et al., 2011). All shRNAs and control scrambled sequence transduction was
performed according to manufacturer’s instructions (Sigma). Luciferase re-
porter assay was based on the pGL4.14 firefly reporter and pRL-CMV renilla
loading control luciferase vectors See also the Supplemental Information.
ChIP, Coimmunoprecipitation, and Protein Translation Assay
ChIPwas performed on the basis of Nelson et al. (2006) using an anti-IRF3 anti-
body (Santa Cruz). Coimmunoprecipitation (coIP) was performed by pull-down
with anti-CEACAM1 5F4 antibody (provided byR.S.B.) conjugated to protein G
sepharose (Santa Cruz) and probing with anti-SHP2 (Santa Cruz) according to
manufacturer’s instructions. For translation analysis, starved cells were then
administered with [35S]Methionine. See also the Supplemental Information.
Statistical Analysis
Statistical significance was determined by Student’s t test. p value of less than
0.05 was considered significant and indicated in figure and figure legends as
Not significant: N.S., *p < 0.05, **p < 0.01, or ***p < 0.001.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.celrep.2016.05.036.
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